文献速递免疫规划

重新审视发展中国家儿童中减毒活流感疫苗的功效

Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
PubMed 文献 · Vaccine · 2023-01-04

本文综述了在发展中国家开展的儿童减毒活流感疫苗(LAIV)功效研究。近期两项随机对照试验评估俄罗斯骨架三价LAIV,疫苗功效在孟加拉国为41%,在塞内加尔为0.0%(针对所有流感病毒株)。作者认为需深入理解LAIV功效差异机制,并建议在选择A(H1N1)pdm09组分时评估复制适应性。

要点

  • 俄罗斯骨架三价LAIV在孟加拉国儿童中疫苗功效为41%,在塞内加尔为0.0%。
  • 2013年前,基于Ann Arbor的LAIV功效优于灭活流感疫苗(IIV)。
  • 2021年印度农村2年随机对照试验显示,LAIV功效显著低于IIV,但第二年两者相当。

核心结论

  • 需要更深入地理解LAIV在发展中国家功效差异的机制。
  • 在选择俄罗斯骨架三价LAIV的年度A(H1N1)pdm09组分时,除抗原性外评估复制适应性至关重要,并可能最终使其在资源匮乏地区广泛使用。

研究设计与样本

  • 本文为综述,总结了近期在发展中国家开展的评估LAIV在儿童中功效的研究。

主要发现

  • 近期两项评估俄罗斯骨架三价LAIV的随机对照试验报告了矛盾结果:针对所有流感病毒株的疫苗功效在孟加拉国为41%,在塞内加尔为0.0%。
  • 2013年前,基于Ann Arbor的LAIV显示出优于IIV的功效。
  • 由于基于Ann Arbor的LAIV对流感A(H1N1)pdm09样病毒效果低,CDC免疫实践咨询委员会(ACIP)建议在2016-17和2017-18流感季节不使用LAIV。
  • A(H1N1)pdm09 LAIV株复制适应性降低被认为是导致基于Ann Arbor的LAIV效果低的原因。
  • A(H1N1)pdm09组分更新后,ACIP将基于Ann Arbor的LAIV重新引入为2018-19流感季节的疫苗选择。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal influenza epidemics cause significant pediatric mortality and morbidity worldwide. Live attenuated influenza vaccines (LAIVs) can be administered intranasally, induce a broad and robust immune response, demonstrate higher yields during manufacturing as compared to inactivated influenza vaccines (IIVs), and thereby represent an attractive possibility for young children in developing countries. We summarize recent pediatric studies evaluating LAIV efficacy in developing countries where a large proportion of the influenza-virus-associated respiratory disease burden occurs. Recently, two randomized controlled trials (RCTs) assessing Russian-backbone trivalent LAIV in children reported contradictory results; vaccine efficacy varied between Bangladesh (41 %) and Senegal (0.0 %) against all influenza viral strains. Prior to 2013, Ann Arbor-based LAIV demonstrated superior efficacy as compared to IIV. However, due to low effectiveness of the Ann Arbor-based LAIV against influenza A(H1N1)pdm09-like viruses, the CDC Advisory Committee on Immunization Practices (ACIP) recommended against the use of LAIV during the 2016-17 and 2017-18 influenza seasons. Reduced replicative fitness of the A(H1N1)pdm09 LAIV strains is thought to have led to the low effectiveness of the Ann-Arbor-based LAIV. Once the A(H1N1)pdm09 component was updated, the ACIP reintroduced the Ann-Arbor-based LAIV as a vaccine choice for the 2018-19 influenza season. In 2021, results from a 2-year RCT evaluating the Russian-backbone trivalent LAIV in rural north India reported that LAIV demonstrated significantly lower efficacy compared to IIV, but in Year 2, the vaccine efficacy for LAIV and IIV was comparable. A profounder understanding of the mechanisms underlying varied efficacy of LAIV in developing countries is warranted. Assessing replicative fitness, in addition to antigenicity, when selecting annual A(H1N1)pdm09 components in the Russian-backbone trivalent LAIVs is essential and may ultimately, enable widespread utility in resource-poor settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bagga S, Krishnan A, Dar L, et al. Revisiting live attenuated influenza vaccine efficacy among children in developing countries. Vaccine. 2023. PMID: 36604216. doi:10.1016/j.vaccine.2022.12.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。